Cargando…
Precision Oncology in Gastrointestinal Stromal Tumors
GIST (gastrointestinal stromal tumors) represent 20% of sarcomatous tumors and 1–2% of primary gastrointestinal cancers. They have an excellent prognosis when localized and resectable, though their prognosis is poor in the metastatic setting, with limited options after the second line until recently...
Autores principales: | Mechahougui, Hiba, Michael, Montemurro, Friedlaender, Alex |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217249/ https://www.ncbi.nlm.nih.gov/pubmed/37232809 http://dx.doi.org/10.3390/curroncol30050351 |
Ejemplares similares
-
Home-deliverable antitumoral treatments in the age of COVID-19: the Portsmouth experience and a narrative review
por: Mechahougui, Hiba, et al.
Publicado: (2022) -
Gastrointestinal stromal tumor
por: Stamatakos, Michael, et al.
Publicado: (2009) -
Gastrointestinal stromal tumors
por: Beham, Alexander W., et al.
Publicado: (2011) -
The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor
por: Liu, Peng, et al.
Publicado: (2020) -
Role of Machine Learning in Precision Oncology: Applications in Gastrointestinal Cancers
por: Tabari, Azadeh, et al.
Publicado: (2022)